Cancer Trial ‘Super Responders’ Pique ASLAN’s Interest
This article was originally published in PharmAsia News
Executive Summary
Singapore's ASLAN has partnered with an Asian genomic profiling firm to examine the gene profiles of cancer patients who respond unusually well to its lead investigational drug, with the aim of identifying new molecular targets.